Try our Advanced Search for more refined results
Life Sciences - February, 2023
311 articles
- Buyers Don't Qualify As Class In Lamictal Antitrust Case
- J&J Judge Rejects 'Whining' MDL Objection, Attys Get $2.5M
- Vidal Wants To Hear More About PTAB's Ruling On Pig Vax IP
- Abbott Wants 26 People Removed From Infant Formula MDL
- Families Blast 'Dehumanizing' Stance As Opioid Trial Closes
- Unilever Can't Nix TRESemme Shampoo User's Hair Loss Suit
- Bayer Must Face False Ad Suit Over 'Natural' Vitamins
- 3rd Circ. Preview: March Roars In With Workplace Disputes
- 2 Takeaways From 3rd Circ.'s J&J Bankruptcy Ruling
- DOJ Wins Kickback Verdict Threatening $485M Liability
- Roe's Demise Revives Texas Suit Over Abortion Services Funding
- FDA Cracks Down On Import Of Tranquilizer Linked To Deaths
- Venable Adds 2 JAG Medical Research Attys To FDA Group
- Life Sciences Group Of The Year: Cooley
- Insys Founder Says Prison Release Could Be 'Life-Saving'
- Chipmakers Can Start Applying For US Subsidies
- Drugmakers To Face Price-Fixing Claims From State AGs
- USTR Urged To Let 4 Countries Bypass Vertex's Trikafta IP
- Norfolk Southern To Allow More Exam Time At Derailment Site
- Ohio, US EPAs Sued Over 'Staged Farce' In Train Derailment
- FTC Pushes To Hold Shkreli In Contempt
- Drug Distributors Not The Cause Of Opioid Harm, Jury Told
- Dow Judge Tells Modesto: Take $16M Or New Punitives Trial
- Generics Makers Settle Liver Drug Patent Fight On Eve Of Trial
- Release Opt Out Trips Up Tricida Ch. 11 Disclosure Approval
- 7th Circ. Backs Humana's ADA Win Over Anxious Worker
- Catching Up With Delaware's Chancery Court
- Steps Lawyers Can Take Following Involuntary Terminations
- Pillsbury IP Litigator Joins Husch Blackwell's DC Office
- Life Sciences Group Of The Year: Latham
- Justices Won't Hear Pharmacist's Appeal In Deadly Outbreak
- 'Crafty' Defense Attys Bombarded In Supreme Court FCA Fight
- Elizabeth Holmes Cites Newborn In Ripping Flight Risk Claim
- Teva, AbbVie Tell 3rd Circ. New Precedent Won't Help Buyers
- A Dozen Dem AGs Sue Over FDA's Abortion Drug Regulations
- Feds Want All $25M Of Insys Founder's Money For Restitution
- ITC Gets An Earful On Impact Of Possible Apple Watch Ban
- BioMarin Hid 'Revolutionary' Drug's Troubles, Investor Says
- FDA Plans Slew Of New Tobacco Program Efforts
- Monster Wants $167M Added To $293M VPX False Ad Verdict
- COVID Testing Firm To Seek Ch. 11 Bids By Early April
- Fed. Circ. Won't Let Jazz Keep System Patent In Orange Book
- High Court Ax Of Atty-Client Privilege Case Deepens Split
- Genus Claims Questions After Justices Deny Juno Rehearing
- Former New Mexico AG Counsel Joins Nachawati Law
- Akorn Files For Ch. 7 Liquidation With Over $100M Debt
- AthenaHealth Fights Whistleblower's Atty Fee Top-Up Request
- Late Filing Gets Westco Chemicals ERISA Suit Tossed
- Life Sciences Group Of The Year: Dechert
- UK Litigation Roundup: Here's What You Missed In London
- Ex-Pharma CEO Can't Undo Landmark Opioid Conviction
- End-Payors Ink $30M Novartis Exforge Deal
- Immunomedics' $40M Deal Over Data Scandal Gets Initial OK
- 6th Circ. Won't Revive Dow Corning Implant Settlement Claims
- Cannabis And Psychedelics Roundup: N.H. Eyes Legalization
- Abortion Pill Fate Hangs On Conservative Judge, 'Zombie' Law
- Warren Asks Feds To Review New Keytruda Patent Requests
- A Method To Measure Pay-For-Delay Drugs' Financial Impact
- Saying J&J Rival Shows 'No Respect,' Judge Issues Sales Ban
- Pharma Exec Traded On Kodak COVID Loan Info, Feds Say
- Ousted Kidney Test Founder Sues Startup Over Legal Fees
- 2 Firms Steer Biotech Firm's $425M Merger With US Rival
- High Court's FCA Showdown Is Already Shaping DOJ Probes
- COVID Test Maker Lucira Health Files For Ch. 11 Protection
- Atty Pushes Back After DOJ Says DEA Not An Agency
- Chamber Of Commerce Says Patent Policy 'Getting Stormy'
- Worker Must Pay For 'Egregious' Claim, Eli Lilly Says
- FDA Wants Plant-Based 'Milk' To Specify Nutrition Differences
- Ex-Judges Slam Panel Swap That Sunk Novartis Patent Win
- End Payors Latest To Drop Bankruptcy-Blocked Par Claims
- Health Orgs Tell 6th Circ. $650M Opioid Verdict Must Stand
- 3rd Circ. Asked To Look At New Precedent In Class Cert. Fight
- In First, FDA Fines E-Cig Cos. Over Unauthorized Products
- Circuit Split Complicates US Discovery In Foreign Tribunals
- Anthem Can't Ditch JetBlue, Alaska Airlines' Price Fixing Suits
- AbbVie, J&J Units Say Del. Judge's Rebukes Bolster Fee Bid
- 8 BigLaw Firms Sign On To New Abortion Defense Initiative
- 3 Job Satisfaction Questions For Partners Considering Moves
- State AGs May Put Investors On The Hook For Co. Bad Acts
- Hidden Costs Of FCA, Anti-Kickback Claims For Public Cos.
- Pa. Justices OK J&J Unit's $2.1M Tax Refund In Sourcing Fight
- Outcome Ex-Growth Chief Says Bad Business Was 'Pervasive'
- Ex-GE Lighting Cos. Owe $2M For Infringing Patent, Jury Says
- White House Won't Veto Potential ITC Apple Watch Ban
- US Chamber, Legal Groups Favor J&J Talc Ch. 11 Rehearing
- Gilead, Janssen And Teva Face HIV Drug Antitrust Trial In May
- Breaking IP Barriers With Banner Witcoff's Mercedes Meyer
- Justices Let SG Join Amgen Case, But Not Chemistry Group
- 50 Cent Settles Penile Enhancement Ad Suit With Publication
- Sorrento Cleared For Ch. 11 Loan Over Nant Entity Objection
- Anika Therapeutics Spars With Caligan Over Corporate Future
- State, Federal Disconnect Sows Confusion For CBD Industry
- French Court Nixes €444M Dominance Fine For Drug Cos.
- Renibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale
- Senate Judiciary Asked To Hold Hearings On 6 Mergers
- Robitussin 'Naturals' Cough Syrup Mislabeled, Suit Says
- 4 Exercises To Quickly Build Trust On Legal Teams
- High Court Won't Review $302M J&J Fine Appeal
- Feds Say Insys Founder's Health Doesn't Merit Early Release
- Fed. Circ. Resurrects Bard's Medical Injection Patents
- Lengthy Delay Dooms LabMD Suit, FTC Attys Tell DC Circ.
- Walmart Rejects Opioid Liability Over 'Unwitting' Pharmacists
- Vegan Dairy Co. Miyoko's Says Namesake Founder Stole IP
- 6th Circ. OKs Preliminary Injunction In Implant Co.'s Suit
- Judge Unwilling To Find Apple Stole Masimo Trade Secrets
- Balwani Fights 13-Year Sentence, $900M Restitution
- Attys Seek Out Of Cancer Patient's Monsanto Civil Rights Suit
- Catching Up With Delaware's Chancery Court
- NJ Justices Expand Factors For Drug Expert Testimony
- DNA Testing Co. Agrees To Beef Up Security After Data Breach
- DEA Erred In Rejecting Psilocybin Therapy, 9th Circ. Hears
- FCA Ruling 'Turned Law On Its Head,' Justices Hear
- 2nd Circ. Tosses Animal Rights FOIA Claim Against USDA
- Illicit Cannabis Is The Problem, Not State-Legal Markets
- Pharma, Consumer Advocates Clash Over FDA-USPTO Collab
- WDTX Judge Won't Send Ravgen Patent Suit Back To Albright
- TTAB Won't Let Diagnostic Co. Register 'NF-Light' TM
- 'Noisy Exit' Hits FTC At Crucial Moment
- Mitsubishi Touts $940M Arbitration Win Over Gilenya Royalties
- Sen. Grassley Plans FCA Amendments Amid 'Absurd' Rulings
- Hearing Aid Co. Eargo Beats Investor Suit Over DOJ Probe
- 8 Steps To Improve The Perception Of In-House Legal Counsel
- Teacher Urges 3rd Circ. To Renew Steroid Whistleblower Suit
- How High Court Amgen Case Could Alter Patent Enablement
- Life Science Investor To Spend €140M On Stock Buyback
- In 3rd Reversal, PTAB Will Eye Seagen Patent In $42M Case
- 3rd Circ. Upholds Dismissal Of Benicar Atty Fee Award Suit
- Flint Questioned On Funding For Residents' Info Requests
- Biotage Will Acquire Astrea Bio Business In $190M Stock Deal
- Bulk Of Human Milk Maker's TM Suit Survives Dismissal Bid
- 'Egregious' Opioid Sales Support $650M Verdict, 6th Circ. Told
- Red Cross Hit With Antitrust Suit For Platelet Treatment Tying
- These Firms Are Pulling In The Most Patent Litigation Work
- Trade Show Demo Sinks Gynecological Patent At Fed. Circ.
- Procedure Rule 7.1 Can Simplify Litigators' Diversity Analysis
- Firms Ask Del. Justices To Undo Fee Bid Denial In Vax Biz Suit
- Glaser Weil, Kirkland Lead $1.36B Sale Of Wyatt Technology
- Patent Suits Mostly Stayed Level In 2022, Yet Appeals Fell
- Moderna Is Wrong Target Of COVID Vax IP Claims, Feds Say
- Medtronic Hogs Surgical Market With Unfair Deals, Rival Says
- Jazz Argues Drug Patent Should Stay In Orange Book
- More Needed On Reproductive Rights, Senate Dems Tell Biden
- Philips Notches X-Ray IP Win After Defendant Goes Silent
- Opioids More Addictive Than Cocaine, Ga. Jury Told
- J&J Talc Unit Seeks 3rd Circ. Rehearing On Ch. 11 Dismissal
- FDA Says Legionnaires' Disease Found On Cruise Ship
- How Companies Could Define 'Social' In ESG Metrics
- DC Hospital Inks Deal To End Suit Over Water Shut-Off, COVID
- LabCorp Fends Off Class Cert., Second Billing Suit In NC
- Ga. Doc Tells 11th Circ. Roundup Claims Not Barred
- Forian Sells Cannabis Software Biz To Alleaves For $30M Cash
- CBD Buyers, Maker Fight Over Stay In Mislabeling Suit
- Biotech Co. Sued In Delaware Over 'Excessive' Director Pay
- 3rd Circ. Ruling Limits Add-On Money Laundering Charges
- FTC's GoodRx Action Highlights Risks For Digital Health Cos.
- Republican FTC Member Wilson Resigning Over Khan Policy
- 'Wake-Up Call': FCA Attys Seek Answers As Fraud Fight Falters
- Feds, Nobel Prize Winner Back Sanofi At High Court IP Fight
- Napa Valley Hilton Sued Over Legionnaires' Disease Outbreak
- Court Told Not To Toss Regeneron's Amgen Bundling Suit
- Azurity Loses Hypertension Drug Patent Trial Against Alkem
- Alcon Inc. To Pay $199 Million To Settle J&J Laser IP Dispute
- What To Expect From The House Select Committee On China
- FTC, States Defend Pesticide Antitrust Suit
- What High Court Case Could Mean For Gene Therapy Patents
- Cos. Sued Over Tainted Eye Drops Linked To Infection
- DEA Says 2 Lab-Derived Cannabis Compounds Are Schedule I
- Durbin Wants Life Science Cos.' Interlocking Boards Reviewed
- J&J Ch. 11 Ruling Highlights 'Texas Two-Step' Skepticism
- LabMD Sues Nonprofit, Dinsmore Over FTC Enforcement Case
- Ex-Theranos Exec Balwani Fights Feds' $900M Restitution Bid
- Fed. Circ. Remains Sour On Dartmouth's Milk Vitamin Patent
- 2 Firms Guide Fashion Distributor's $707M SPAC Merger
- Investor In Genomic Test Co. SPAC Sues Its Board In Del.
- Texas' Medical Cannabis Program May Soon Be Sittin' Pretty
- Merck, Glenmark Must Face Zetia Antitrust MDL At April Trial
- Catching Up With Delaware's Chancery Court
- Sorrento Therapeutics Hits Ch. 11 With Over $100M In Debt
- Roche Rips Bank's Counterclaims In $87M Test Strip Row
- Shkreli Says His New Co. Doesn't Violate FTC's Pharma Ban
- Patheon Claims Arranta Figures Lied In Chancery Trial
- Red And Blue State AGs Join Legal Fight Over Abortion Pill
- Opioid Judge Targets 'Unfortunate' Gaps In Pharmacy Deals
- EpiPen Rebates Help Middlemen, Not Patients, Justices Told
- HIV Drug Buyers Rip Gilead's Dismissal Bid As 'Nothing New'
- Quest Diagnostics Accused Of 'Abusive' Billing Practices
- What DOJ's 2022 Recovery Stats Say About FCA Enforcement
- Latham-Led Biotech, Renewable Energy Firms Price 2 IPOs
- Law360 Seeks Members For Its 2023 Editorial Boards
- Pillsbury Adds Perkins Coie Venture Capital Atty In Calif.
- Robins Kaplan Adds Gov't Relations Atty From Jackson Lewis
- 3 Firms Guide Pair Of Blank-Check IPOs Totaling $160M
- Atty Conflict Discussions In Idaho Murder Case And Beyond
- Conn. Docs Not Liable For Pot User's Lies About PTSD
- UK Litigation Roundup: Here's What You Missed In London
- HSF Hires 5-Atty Team From Simmons & Simmons In Italy
- Teva Slams Lilly's 'Scorched-Earth' Tactics In Migraine Battle
- HHS Memos, 5 Senate Bills Target Drug Prices And Tactics
- Syngenta, Corteva Pesticide Antitrust Cases Centralized In NC
- Fed. Circ. Affirms Partial Ax Of Guardant Genetic Test Patent
- Courts Must Apply Correct Causal Standard In Kickback Cases
- South Korea Fines German Auto Cos. $33M Over Emissions
- Bayer Unit Asks 3rd Circ. To Keep Roundup Suit Federal
- THC False Ad Plaintiffs Oppose Dismissal Conditions
- Chicago Says Dobbs Decision Forecloses Vax Challenge
- How A Dusty Law Review Article Entered The Post-Roe Debate
- Higher Ed Can't Recycle Cannabis Policies For Psychedelics
- Why The Original 'Rocket Docket' Will Likely Resume Its Pace
- Orrick Lures Ex-Hughes Hubbard Arbitration Pro To NY Office
- 1st Circ. Unsure Polling Gaffes Merit Automatic New Trial
- Globus Medical, NuVasive Combine In $3.1B All-Stock Merger
- Sens. Call Out Health Cos. For Sharing Data With Advertisers
- Merck Seeks Dismissal Of NC Gardasil Vax Claims
- Illustrator Tries Again To Keep $3.6M Infringement Award
- Fed. Circ. Mulls Amgen-Sandoz Psoriasis Drug Dispute
- Fla. Judge Orders Halt To Infringing Canine Implant Sales
- Centene Cuts $215M False Claims Act Deal With Calif. AG
- Consumers And Insurers Get Class Cert. In Valsartan MDL
- Eli Lilly Hit With New Age Bias Suit Over Millennial Push
- Chancery Nixes Early Trial On Masimo Board Control Defense
- NotPetya Triggers War Exclusion, Insurers Tell NJ Panel
- Medical Equipment Suppliers Convicted Of $3.8M Fraud
- Medtronic Unit Hit With $106.5M Heart Valve Patent Trial Loss
- Vitamin Shoppe Hyped Weak Muscle Powder, 1st Circ. Told
- An Applicant's Guide To USPTO's Examiner Incentive System
- Viela Bio Shareholders Sue AstraZeneca In Del. After $3B Sale
- Investors In Conn. Ultrasonics Co. Sue For Share Appraisal
- CBD Co. Copied Trademark, Vitamin Co. Says
- White House Seeks More US-Made Materials For Infrastructure
- Texas Says HHS Can't Make Pharmacies Sell Abortion Pills
- DOJ Reveals One Of FCA's Smallest Hauls In Many Years
- Philip Morris Patent Fight Has Fed. Circ. About To Combust
- Zantac Plaintiffs Must File Separate Complaints, Judge Says
- The Pill Club To Pay $15M To Settle Medi-Cal Fraud Claims
- Drug Execs Testify About DEA Compliance In Ga. Opioid Trial
- Instacart Co-Founder Hit With TRO In Trade Secrets Fight
- FTC Shows Privacy Heft With Groundbreaking GoodRx Action
- Sullivan & Worcester Launches Boston Permitting Practice
- Ionis Shareholders Come Together In Del. Pay Suit Deal
- Sorrento Can't Nix $175M Arbitration Loss To LA Times Owner
- EU To Consider Ban On Toxic 'Forever Chemicals'
- Kraft Says Class Needs To Back Up Capri Sun PFAS Suit
- Medicare Developments Ahead For Remote Health Monitoring
- Jury Finds Capital Inventory's Ex-Execs Stole Trade Secrets
- Bankruptcies Aren't The Real Problem In Mass Tort System
- The Discipline George Santos Would Face If He Were A Lawyer
- Pharma Co. Sued In Del. For Docs On Undisclosed IP Value
- DC Court Nixes Challenge To Canadian Medicine Import Rule
- Shift In Health Care Antitrust Prosecutions Is Likely
- Masimo Rolls Back Board Control Shields Targeted In Del. Suit
- Ex-NC Sen. Burr Joins DLA Piper As Principal Policy Adviser
- 'No Surprises' Medical Billing Rule Is Still Illegal, Judge Rules
- Pfizer Must Produce Exchanges With FBI In Data Swiping Suit
- Ohio Abortion Clinics Tell Justices To Leave Block On Law
- Cos. Sued Over Recalled Eyedrops Linked To Outbreak
- Eli Lilly Worker's Proposed Class Suit Over 401(k) Fees Nixed
- Ga. Family Reveals Generational Opioid Addiction At Trial
- PTAB Again Axes Cochlear Implant IP After Vidal Remand
- How FTC's Broadened Health Ad Guidance Affects Marketers
- Labcorp Inks $19M False Claims Act Deal In 10-Year-Old Case
- PhaseBio Suitor Gets $2M Breakup Fee Without Ch. 11 Auction
- Catching Up With Delaware's Chancery Court
- Seyfarth Accused Of Ushering Bad Deal On Companies' Sale
- Ohio Neurologist Given 2½ Years For Drug Kickback Scheme
- Barnes & Thornburg Grows In NJ, Pa. With 5 New Attys
- Ex-Rep. Ron Kind Joins Arnold & Porter Public Policy Group
- Opioids Ravaged Ga. Family, Jury Told In Distributor Case
- Sanofi Urges Justices To Deny Amgen's 'Monopoly' Attempt
- GoodRx Holdings Hit With Class Action Over Data Sharing
- 10th Circ. Erases CSA Convictions After High Court Ruling
- Philip Morris Says Baltimore Litter Rules Usurp Federal Law
- Cooley, Latham Steer Biotech Startup's Upsized $161M IPO
- Australia Legalizes Prescribing Of Psilocybin And MDMA
- 'Green Shoots' Start To Emerge From A Bruised IPO Market
- DC Circ. Won't Revisit Revival Of Pharma Terror-Funding Case
- Masimo Urges Chancery To Uphold Founder's Takeover Shield
- Pending FDA Cosmetics Review Allows Class Action Defense
- Health Hires: Manatt Phelps, vTv Therapeutics
- A Litigation Move That Could Conserve Discovery Resources
- Issues To Watch In Fla.'s Telehealth Genetic Counseling Bills
- 20 AGs Warn CVS, Walgreens Against Mailing Abortion Pills
- ITC Clears Cannabis Cos. In Vaping IP Investigation
- Harvard Ducks Some Vizgen Counterclaims In Patent Row
- IP Forecast: Fed. Circ. To Eye Cooley's Conduct In CBD Row
- 11th Circ. Affirms Injured Pelvic Mesh Patient's Trial Win
- Ex-USPTO Chiefs Say Patent System 'Overhaul' Not Needed
- Questions Surround FDA's Orphan Drug Exclusivity Approach
- Litigators Should Approach AI Tools With Caution
- Pharmacy Tech Co. Gets Partial Costs In Defense Deal Dispute
- Goodwin Adds 4 More Troutman Attys In Philadelphia And NY
- Lamictal Drug Buyers Lose Another Class Certification Bid
- O'Melveny Adds Finnegan Practice Group Leader In DC
- Latham Adds Gunderson Dettmer Emerging Cos. Atty In Calif.
- Regeneron Says DOJ Cried Fraud 'Despite Knowing The Truth'
- Psychedelics Bill Roundup: Wash. State Mulls Psilocybin
- Canadian, Israeli Cannabis Cos. Terminate $35M Merger Deal
- Fla. Mental Health Provider Is Sued Over Patient Data Breach
- Eisai Settles Recalled Diet Drug Cancer Claims
- Biotech Co. Seeks $3.62M From Shipper Over Frozen Medicine
- FDA Outlines Views Of Clinical Trials Without Placebo Groups
- Hospital's Bid For Pandemic Bonuses Nixed By Old Policy
- Magistrate Judge Advises Cutting Illumina's Gene IP Theft Suit
- Christopher Warren Joins Buchanan Ingersoll As Counsel
- Integra GC Dinged By NJ Ethics Board Over Pa. License Lapse
- Vanda Sues FDA Over Approval Of Teva Generic Sleep Drug
- Duane Morris Adds 2 Ex-Oblon McClelland IP Partners In DC
- Insys Founder Asks To Leave Prison After 2 Heart Attacks
- Boston Scientific Hit With $42M Stent Patent Verdict
- Kirkland-Led Patient Square Clinches Record $3.9B Fund
- FTC Targets GoodRx In 1st Action Under Health Breach Rule
- Wilson Sonsini Expands In DC With Longtime SEC Atty